This site contains promotional information intended only for healthcare professionals resident in the United Kingdom

Visit Pfizer Medical site

Menu

Close

Sign InLog Out
  • EN
Single LinkDropdownLabelLinkLinkLinkLinkLinked DropdownLabelLinkLinkLinkLinkMega MenuHeading

Example of description text sitting alongside header

LabelLinkLinkLinkLinkLabelLinkLinkLinkLinkLabelLinkLinkLinkLink
Linked Mega MenuHeading

Example of description text sitting alongside header

LabelLinkLinkLinkLinkLabelLinkLinkLinkLinkLabelLinkLinkLinkLink
EN - EnglishSelect a languageLanguagesEN - EnglishFR - Françias

Menu

Close

Sign InLog Out
  • EN
Single LinkDropdownLabelLinkLinkLinkLinkLinked DropdownLabelLinkLinkLinkLinkMega MenuHeading

Example of description text sitting alongside header

LabelLinkLinkLinkLinkLabelLinkLinkLinkLinkLabelLinkLinkLinkLink
Linked Mega MenuHeading

Example of description text sitting alongside header

LabelLinkLinkLinkLinkLabelLinkLinkLinkLinkLabelLinkLinkLinkLink
EN - EnglishSelect a languageLanguagesEN - EnglishFR - Françias
Search

Menu

Close

Sign In or RegisterLog Out
Pfizer MedicinesTherapy AreasExplore ContentEventsVideosMaterialsFeatured ArticlesLet’s ConnectSupplyAlliance HealthcareOff-contract claims

Adverse event reporting can be found at the bottom of the page

Menu

Close

AboutAboutPathogen CoveragePatient Risk FactorsAntimicrobial Subscription Model PilotDosingDosingDosingPreparation GuideShelf Life and StorageEfficacy & SafetyEfficacy & SafetyMechanism of ActionREPROVE Phase III trial(HAP/VAP)RECLAIM Phase III trial(cIAI)RECAPTURE Phase III trial(cUTI)REPRISE Phase III trial(cIAI and cUTI)Safety and TolerabilityEfficacy and Safety Data for Paediatric PatientsSupport & ResourcesSupport & ResourcesAMS ResourcesSepsisWebinars (Live and On-demand)KOL Videos - ZaviceftaKOL Videos - Gram-negativeKOL Videos - Clinical experienceVideosMaterials

Information on how to access prescribing information and adverse event reporting can be found towards the bottom of the page.

ZAVICEFTA®: As effective as a carbapenem in hospitalised patients with aerobic Gram-negative cIAIs15, cUTIs16 or HAP, including VAP17 

Overall Risk Factors

HAP/ VAP Patient Profile

cIAI Patient Profile

cUTI Patient Profile

In the face of growing antimicrobial resistance, treatment options are urgently needed for patients at risk of MDR Gram-negative infections7,8

Risk factors for MDR Gram-negative infections2-6

Identifying patients at risk of MDR Gram-negative infections is vital for appropriate selection of adequate, early antimicrobial therapy to reduce the risk of fatal outcomes.8

Early adequate antibacterial therapy is crucial for patients with serious Gram-negative infections8,9

Failure to treat early and appropriately can lead to fatal outcomes in patients with serious Gram-negative infections.8,9**Explore more
Learn about ZAVICEFTA dosing across patient populations, preparation & administration, and shelf life & storage. Access dosing guide Loading Access results of ZAVICEFTA Phase III clinical trials in adult patients with cUTI, cIAI or HAP/VAP​ View Phase III trial​ Loading

Footnotes:

**Early treatment must consider patient risk factors as well as local epidemiology.8
*30-day mortality rate among patients with P. aeruginosa bacteraemia who received delayed effective antimicrobial therapy’.10
30-day mortality among 909 patients with BSIs caused by ESBL-producing K. pneumoniae (n=222) and E. coli (n=687). 11
28-day mortality among 205 patients with BSIs caused by carbapenemase-producing K. pneumoniae (KPC and/or VIM). 12
§30-day mortality among 40 patients with BSIs caused by OXA-48 -producing Enterobacteriaceae.13
IIOverall mortality among 53 patients with BSIs caused by KPC-producing K. pneumoniae.14

Abbreviations:

cUTI, complicated urinary tract infection, cIAI, complicated intra-abdominal infection; HAP, hospital-acquired pneumonia; VAP, ventilator-associated pneumonia; MDR, multi-drug resistant; BL/BLI, β-lactam/β-lactamase inhibitors; CRE, carbapenem-resistant Enterobacteriaceae; KPC, Klebsiella pneumoniae carbapenemase; K. pneumoniae, Klebsiella pneumoniae;  MBL, metallo-β-lactamase; OXA, oxacillinase; ESBL, extended-spectrum β-lactamase; P. aeruginosa, Pseudomonas aeruginosa;  CrCl, creatinine clearance; AMR, Antimicrobial Resistance; CVC central venous catheter; ICU intensive care unit. AE, adverse event; CE, clinically evaluable; CI, confidence interval; cMITT, clinically modified intention-to-treat; TOC, test of cure;

Prescribing information

Click here for Zavicefta® (ceftazidime and avibactam) Prescribing Information

Click here for Meronem® (meropenem trihydrate) Prescribing Information

 

References

ZAVICEFTA. Summary of Product CharacteristicsBassetti M, et al. Exp Rev Anti Infect Ther 2017;15:55–65Miller BM, et al. Am J Infect Control 2016;44:134–7De Waele J, et al. Intensive Care Med 2018;44:189–96Albur M, et al. Ann Clin Microbiol Antimicrob 2016;15:23Harris AD, et al. Emerg Infect Dis 2007;13:1144–9Timsit JF, et al. Intensive Care Med 2019;45:172–89 Bonine NG, et al. Am J Med Sci 2019;357:102–10Raman G, et al. BMC Infect Dis 2015;15:395Kang CI, et al. Clin Infect Dis 2003;37:745–51Scheuherman O, et al. Infect Control Hosp Epidemiol 2018;39:660–7Daikos GL, et al. Antimicrob Agents Chemother 2014;58:2322–8Navarro-San Francisco C, et al. Clin Microbiol Infect 2012;19:E72–9Zarkotou O, et al. Clin Microbiol Infect 2011;17:1798–803Mazuski JE, et al. Clin Infect Dis 2016;62:1380–9Wagenlehner FM, et al. Clin Infect Dis 2016;63:754–62Torres A, et al. Lancet Infect Dis 2017;EpubMicek ST, et al. Crit Care 2015;19:219Sartelli M, et al. World J Emerg Surg 2017;12:22Flores-Mireles AL, et al. Nat Rev Microbiol 2015;13:269–84 
PP-ZVA-GBR-1765. March 2023
Identifying patients with HAP/VAP at high-risk of MDR Gram-negative infections

“It is critical for clinicians to identify patients at risk of multi-drug resistance from the onset of infection”18

Patient Profile: Charles – 78-year-old male*

*The example described here is not an actual patient, but rather a fictitious representation of a scenario for which ZAVICEFTA could be considered. 

Risk Factors in a HAP/VAP Patient2-4,21
Scroll left to view table
Patient History:
 
  • Smoker for >45 years
  • Immunosuppressed
  • Frequent travel
  • Chronic renal insufficiency
  • Recent fall at home
Symptoms (developed after 4 days in hospital following fall at home):
  • Wheezing
  • Purulent sputum
  • Leukocytosis
  • Tachypnea
  • Cough
  • Sweating
Diagnosis:
  • Hospital-acquired pneumonia
Suspected Pathogens:
  • MDR Gram-negative pathogens including K. pneumoniae, E. coli, P. aeruginosa 
  • Based on patient’s disease severity, there is concern about potential involvement of carbapenem-resistant strains. 
Learn about ZAVICEFTA dosing across patient populations, preparation & administration, and shelf life & storage. Access dosing guide Loading Access results of ZAVICEFTA Phase III clinical trials in adult patients with cUTI, cIAI or HAP/VAP​ View Phase III trial​ Loading

Abbreviations

​​​​​​​cUTI, complicated urinary tract infection, cIAI, complicated intra-abdominal infection; HAP, hospital-acquired pneumonia; VAP, ventilator-associated pneumonia; MDR, multi-drug resistant; BL/BLI, β-lactam/β-lactamase inhibitors; CRE, carbapenem-resistant Enterobacteriaceae; KPC, Klebsiella pneumoniae carbapenemase; K. pneumoniae, Klebsiella pneumoniae;  MBL, metallo-β-lactamase; OXA, oxacillinase; ESBL, extended-spectrum β-lactamase; P. aeruginosa, Pseudomonas aeruginosa;  CrCl, creatinine clearance; AMR, Antimicrobial Resistance; CVC central venous catheter; ICU intensive care unit. AE, adverse event; CE, clinically evaluable; CI, confidence interval; cMITT, clinically modified intention-to-treat; TOC, test of cure;

Prescribing information

 

Click here for Zavicefta® (ceftazidime and avibactam) Prescribing Information

Click here for Meronem® (meropenem trihydrate) Prescribing Information

 

References

ZAVICEFTA. Summary of Product CharacteristicsBassetti M, et al. Exp Rev Anti Infect Ther 2017;15:55–65Miller BM, et al. Am J Infect Control 2016;44:134–7De Waele J, et al. Intensive Care Med 2018;44:189–96Albur M, et al. Ann Clin Microbiol Antimicrob 2016;15:23Harris AD, et al. Emerg Infect Dis 2007;13:1144–9Timsit JF, et al. Intensive Care Med 2019;45:172–89 Bonine NG, et al. Am J Med Sci 2019;357:102–10Raman G, et al. BMC Infect Dis 2015;15:395Kang CI, et al. Clin Infect Dis 2003;37:745–51Scheuherman O, et al. Infect Control Hosp Epidemiol 2018;39:660–7Daikos GL, et al. Antimicrob Agents Chemother 2014;58:2322–8Navarro-San Francisco C, et al. Clin Microbiol Infect 2012;19:E72–9Zarkotou O, et al. Clin Microbiol Infect 2011;17:1798–803Mazuski JE, et al. Clin Infect Dis 2016;62:1380–9Wagenlehner FM, et al. Clin Infect Dis 2016;63:754–62Torres A, et al. Lancet Infect Dis 2017;EpubMicek ST, et al. Crit Care 2015;19:219Sartelli M, et al. World J Emerg Surg 2017;12:22Flores-Mireles AL, et al. Nat Rev Microbiol 2015;13:269–84 ​​​Torres A, et al. European Respiratory Journal 2017 50: 1700582;Sartelli, et al.  CIAO study. World J Emerg Surg 2012;5-6Gomila A, et al. Infection and Drug Resistance 2018:11 2571–2581Zilberberg M D, et al. Antimicrob Agents Chemother 2020;63:e00346-20
PP-ZVA-GBR-1765. March 2023
Identifying patients with cIAIs at high-risk of MDR Gram-negative infections.

“...appropriate antimicrobial therapy dictated by patient and infection risk factors…is a cornerstone in the management of intra-abdominal infections”
Sartelli M, et al. (2017)19

Patient Profile: Michael – 75-year-old male*

*The example described here is not an actual patient, but rather a fictitious representation of a scenario for which ZAVICEFTA could be considered Sartelli M, et al. (2017)19

Risk Factors in a cIAI Patient22
Scroll left to view table
Patient History:
 
  • Type II diabetes mellitus
  • Underwent segmental colon resection and primary anastomosis with peri-operative antibiotic therapy
  • Previous broad-spectrum IV antibiotic use
  • Recent travel
Symptoms:
 
  • Acute onset abdominal pain that developed into diffuse pain
  • Fever
  • Loss of appetite
  • Nausea 
Diagnosis:
  • Complicated diverticulitis and diarrhoea following admission to the ICU
Suspected Pathogens:
  • MDR Gram-negative pathogens including K. pneumoniae, possibly carbapenem- and colistin- resistant 
Learn about ZAVICEFTA dosing across patient populations, preparation & administration, and shelf life & storage. Access dosing guide Loading Access results of ZAVICEFTA Phase III clinical trials in adult patients with cUTI, cIAI or HAP/VAP​ View Phase III trial​ Loading

Abbreviations

cUTI, complicated urinary tract infection, cIAI, complicated intra-abdominal infection; HAP, hospital-acquired pneumonia; VAP, ventilator-associated pneumonia; MDR, multi-drug resistant; BL/BLI, β-lactam/β-lactamase inhibitors; CRE, carbapenem-resistant Enterobacteriaceae; KPC, Klebsiella pneumoniae carbapenemase; K. pneumoniae, Klebsiella pneumoniae;  MBL, metallo-β-lactamase; OXA, oxacillinase; ESBL, extended-spectrum β-lactamase; P. aeruginosa, Pseudomonas aeruginosa;  CrCl, creatinine clearance; AMR, Antimicrobial Resistance; CVC central venous catheter; ICU intensive care unit. AE, adverse event; CE, clinically evaluable; CI, confidence interval; cMITT, clinically modified intention-to-treat; TOC, test of cure;

Prescribing information

 

Click here for Zavicefta® (ceftazidime and avibactam) Prescribing Information

Click here for Meronem® (meropenem trihydrate) Prescribing Information

 

References

ZAVICEFTA. Summary of Product CharacteristicsBassetti M, et al. Exp Rev Anti Infect Ther 2017;15:55–65Miller BM, et al. Am J Infect Control 2016;44:134–7De Waele J, et al. Intensive Care Med 2018;44:189–96Albur M, et al. Ann Clin Microbiol Antimicrob 2016;15:23Harris AD, et al. Emerg Infect Dis 2007;13:1144–9Timsit JF, et al. Intensive Care Med 2019;45:172–89 Bonine NG, et al. Am J Med Sci 2019;357:102–10Raman G, et al. BMC Infect Dis 2015;15:395Kang CI, et al. Clin Infect Dis 2003;37:745–51Scheuherman O, et al. Infect Control Hosp Epidemiol 2018;39:660–7Daikos GL, et al. Antimicrob Agents Chemother 2014;58:2322–8Navarro-San Francisco C, et al. Clin Microbiol Infect 2012;19:E72–9Zarkotou O, et al. Clin Microbiol Infect 2011;17:1798–803Mazuski JE, et al. Clin Infect Dis 2016;62:1380–9Wagenlehner FM, et al. Clin Infect Dis 2016;63:754–62Torres A, et al. Lancet Infect Dis 2017;EpubMicek ST, et al. Crit Care 2015;19:219Sartelli M, et al. World J Emerg Surg 2017;12:22Flores-Mireles AL, et al. Nat Rev Microbiol 2015;13:269–84 ​​​Torres A, et al. European Respiratory Journal 2017 50: 1700582;Sartelli, et al.  CIAO study. World J Emerg Surg 2012;5-6Gomila A, et al. Infection and Drug Resistance 2018:11 2571–2581Zilberberg M D, et al. Antimicrob Agents Chemother 2020;63:e00346-20
PP-ZVA-GBR-1765. March 2023
Identifying patients with cUTI at high-risk of MDR Gram-negative infections

"In the face of increasing rates of antimicrobial resistance in complicated urinary tract infections (cUTIs), clinicians need to understand cross-resistance patterns among commonly encountered pathogens." Zilberberg M D, et al (2020)24

Patient Profile: Rosa – 56-year old female*

*The example described here is not an actual patient, but rather a fictitious representation of a scenario for which ZAVICEFTA could be considered. 

Risk Factors in a cUTI Patient2-5
Scroll left to view table
Patient History:
  • Undergoing chemotherapy following mastectomy for node-positive, left-sided breast cancer
  • Neutropenic (chemotherapy related)
  • Immunosuppressed
  • Recent carbapenem treatment
Symptoms:
  • Presented with frequent urination and loin pain 
  • Dysuria
  • Fever
  • Disorientation/ confusion
  • Symptoms ongoing for >36 hours
Diagnosis:
  • cUTI with sepsis
Suspected Pathogens:
  • K. pneumoniae, including those resistant to carbapenems (KPC). 
Learn about ZAVICEFTA dosing across patient populations, preparation & administration, and shelf life & storage. Access dosing guide Loading Access results of ZAVICEFTA Phase III clinical trials in adult patients with cUTI, cIAI or HAP/VAP​ View Phase III trial​ Loading

Abbreviations

cUTI, complicated urinary tract infection, cIAI, complicated intra-abdominal infection; HAP, hospital-acquired pneumonia; VAP, ventilator-associated pneumonia; MDR, multi-drug resistant; BL/BLI, β-lactam/β-lactamase inhibitors; CRE, carbapenem-resistant Enterobacteriaceae; KPC, Klebsiella pneumoniae carbapenemase; K. pneumoniae, Klebsiella pneumoniae;  MBL, metallo-β-lactamase; OXA, oxacillinase; ESBL, extended-spectrum β-lactamase; P. aeruginosa, Pseudomonas aeruginosa;  CrCl, creatinine clearance; AMR, Antimicrobial Resistance; CVC central venous catheter; ICU intensive care unit. AE, adverse event; CE, clinically evaluable; CI, confidence interval; cMITT, clinically modified intention-to-treat; TOC, test of cure;

Prescribing information

 

Click here for Zavicefta® (ceftazidime and avibactam) Prescribing Information

Click here for Meronem® (meropenem trihydrate) Prescribing Information

 

References

ZAVICEFTA. Summary of Product CharacteristicsBassetti M, et al. Exp Rev Anti Infect Ther 2017;15:55–65Miller BM, et al. Am J Infect Control 2016;44:134–7De Waele J, et al. Intensive Care Med 2018;44:189–96Albur M, et al. Ann Clin Microbiol Antimicrob 2016;15:23Harris AD, et al. Emerg Infect Dis 2007;13:1144–9Timsit JF, et al. Intensive Care Med 2019;45:172–89 Bonine NG, et al. Am J Med Sci 2019;357:102–10Raman G, et al. BMC Infect Dis 2015;15:395Kang CI, et al. Clin Infect Dis 2003;37:745–51Scheuherman O, et al. Infect Control Hosp Epidemiol 2018;39:660–7Daikos GL, et al. Antimicrob Agents Chemother 2014;58:2322–8Navarro-San Francisco C, et al. Clin Microbiol Infect 2012;19:E72–9Zarkotou O, et al. Clin Microbiol Infect 2011;17:1798–803Mazuski JE, et al. Clin Infect Dis 2016;62:1380–9Wagenlehner FM, et al. Clin Infect Dis 2016;63:754–62Torres A, et al. Lancet Infect Dis 2017;EpubMicek ST, et al. Crit Care 2015;19:219Sartelli M, et al. World J Emerg Surg 2017;12:22Flores-Mireles AL, et al. Nat Rev Microbiol 2015;13:269–84 ​​​Torres A, et al. European Respiratory Journal 2017 50: 1700582;Sartelli, et al.  CIAO study. World J Emerg Surg 2012;5-6Gomila A, et al. Infection and Drug Resistance 2018:11 2571–2581Zilberberg M D, et al. Antimicrob Agents Chemother 2020;63:e00346-20
PP-ZVA-GBR-1765. March 2023
Learn more about the tolerability data of ZAVICEFTA from four Phase III clinical trials. View safety profile Loading

Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard or search 

for MHRA Yellow Card in Google Play or Apple App Store

 

Adverse events should also be reported to Pfizer Medical Information on 01304 616161

PfizerPro Account

To access further materials, resources and receive communication about medicines and vaccines promoted by Pfizer.

Sign In or RegisterAccountSign Out

This site is intended only for healthcare professionals resident in the United Kingdom. If you are a member of the public wishing to access information on a specific medicine, please visit www.medicines.org.uk/emc

 

This website is brought to you by Pfizer Limited, a company registered in England 

and Wales under No. 526209 with its registered office at Ramsgate Road, Sandwich, Kent, CT13 9NJ

 

Copyright © 2024 Pfizer Limited. All rights reserved.

 

VAT registration number GB201048427

PP-UNP-GBR-7866. January 2024
For UK Healthcare Professionals*

These pages are not intended for patients or for members of the general public. The healthcare professional web pages contain promotional content.

I confirm that I am a healthcare professional* resident in the United Kingdom.

If you select 'No', you will be redirected to Pfizer.co.uk where you will be able to access reference information on Pfizer's prescription medicines.

*The ABPI Code definition for healthcare professional is members of the medical, dental, pharmacy and nursing professionals and any other persons who in the course of their professional activities may administer, prescribe, purchase, recommend or supply a medicine.

PP-UNP-GBR-7812. January 2024

YesNo
You are now leaving PfizerPro​​​​​

​​​​​​​You are now leaving www.pfizerpro.co.uk. Links to external websites are provided as a resource to the viewer. This website is neither owned or controlled by Pfizer Ltd. 

Pfizer accepts no responsibility for the content or services of the linked site.​​​​​​​​​​​​​​

​​​​​​​PP-PFE-GBR-3858. November 2021​​​​​​​
​​​​​​​
You are now leaving PfizerPro
​​​​​​​
​​​​​​​You are now leaving www.pfizerpro.co.uk. Links to external websites are provided as a resource to the viewer. This website is neither owned nor controlled by Pfizer Ltd. 

Pfizer accepts no responsibility for the content or services of the linked site other than the information or other materials relating to ​​​​​Pfizer medicines or 
business which it has provided or reviewed.

PP-PFE-GBR-3859. November 2021
​​​​​​​